Literature DB >> 10500306

Antithrombin agents as adjuncts to thrombolytic therapy.

J K French1, H D White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10500306     DOI： 10.1023/a:1008975216841

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  29 in total

Review 1.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.

Authors:  R Collins; R Peto; C Baigent; P Sleight
Journal:  N Engl J Med       Date:  1997-03-20       Impact factor: 91.245

2.  Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction.

Authors:  H D White; D B Cross; J M Elliott; R M Norris; T W Yee
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

3.  Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.

Authors:  H D White; P E Aylward; M J Frey; A A Adgey; R Nair; W S Hillis; Y Shalev; M A Brown; J K French; R Collins; J Maraganore; B Adelman
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

4.  Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.

Authors:  P R Eisenberg; J P Miletich
Journal:  Thromb Res       Date:  1989-09-01       Impact factor: 3.944

5.  Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor.

Authors:  D R Abendschein; Y Y Meng; S Torr-Brown; B E Sobel
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

6.  Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study.

Authors: 
Journal:  Eur Heart J       Date:  1987-06       Impact factor: 29.983

7.  Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.

Authors:  M Galvani; D R Abendschein; D Ferrini; F Ottani; F Rusticali; P R Eisenberg
Journal:  J Am Coll Cardiol       Date:  1994-11-15       Impact factor: 24.094

8.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  Activation/inactivation of human factor V by plasmin.

Authors:  C D Lee; K G Mann
Journal:  Blood       Date:  1989-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.